Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma

Clinical Trial ID NCT01369888

Rank	Title	Journal	Year	PubWeight™‹?›
1	Cancer statistics, 2007.	CA Cancer J Clin	2007	53.49
2	High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.	J Clin Oncol	1999	10.86
3	Chemotherapy for metastatic melanoma: time for a change?	Cancer	2007	1.99
4	Interleukin-15 biology and its therapeutic implications in cancer.	Trends Pharmacol Sci	2011	1.64
5	Trial watch: Chemotherapy with immunogenic cell death inducers.	Oncoimmunology	2012	1.33
6	Trial Watch: Adoptive cell transfer immunotherapy.	Oncoimmunology	2012	1.18
7	Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer.	Scientifica (Cairo)	2014	0.94
8	Common gamma chain cytokines in combinatorial immune strategies against cancer.	Immunol Lett	2015	0.91
9	Molecular pathways: interleukin-15 signaling in health and in cancer.	Clin Cancer Res	2014	0.90
10	IL15 and T-cell Stemness in T-cell-Based Cancer Immunotherapy.	Cancer Res	2015	0.81
11	Targeting CD8+ T-cell tolerance for cancer immunotherapy.	Immunotherapy	2014	0.81
12	High-density lipoproteins delivering interleukin-15.	Oncoimmunology	2013	0.75
13	KLRG1(+) natural killer cells protect against pulmonary metastatic disease by immunosurveillance.	Oncoimmunology	2014	0.75